Resolutions passed in the 33rd AGM of the Company held on 29th September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech held its 33rd Annual General Meeting on 29th September 2025 via video conferencing, and shareholders approved all 18 resolutions with the requisite majority. Key approvals include the adoption of audited financial statements for FY ending March 31, 2025, reappointment of three directors, and new appointments of three Whole-time Directors and one Independent Director, each for a five-year term. Shareholders also approved increasing the company's authorized share capital to Rs. 85 crore, divided into 8.5 crore equity shares of Rs. 10 each. Several material related party transactions with subsidiaries (Dindigul Farm Product, Matrix Boilers, IBL Healthcare, HSL Agri Solutions, HSLPrime Properties, and IBL Investments) were cleared. Notably, shareholders approved the disinvestment from Dindigul Farm Product Limited (DFPL), a material subsidiary that contributed 47.11% of consolidated turnover (Rs. 6,282.81 lakhs) and 35.24% of consolidated net worth (Rs. 3,521.13 lakhs) in FY25. Mr. K. Ravichandran was appointed as Secretarial Auditor.
The biggest implication for shareholders is the approved disinvestment of DFPL, which makes up nearly half of consolidated revenue, signaling a major reshaping of the company's business portfolio. The authorized capital hike to Rs. 85 crore and multiple related-party transaction approvals with subsidiaries indicate the company is gearing up for restructuring or expansion activities. Investors should watch for details on the DFPL sale (consideration, buyer, timeline) as this will materially affect future consolidated financials.